urticariatreatmentreport.com valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot /
BingBot /
BaiduSpider /
YandexBot /
Meta Tags
Title Urticaria Treatment
Description www.UrticariaTreatmentReport.com
Keywords N/A
Server Information
WebSite urticariatreatmentreport faviconurticariatreatmentreport.com
Host IP 34.73.45.65
Location United States
Related Websites
Site Rank
More to Explore
urticariatreatmentreport.com Valuation
US$682
Last updated: 2023-05-02 17:47:30

urticariatreatmentreport.com has Semrush global rank of 0. urticariatreatmentreport.com has an estimated worth of US$ 682, based on its estimated Ads revenue. urticariatreatmentreport.com receives approximately 78 unique visitors each day. Its web server is located in United States, with IP address 34.73.45.65. According to SiteAdvisor, urticariatreatmentreport.com is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$682
Daily Ads Revenue US$0
Monthly Ads Revenue US$18
Yearly Ads Revenue US$226
Daily Unique Visitors 5
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
urticariatreatmentreport.com. 3599 IN A IP: 34.73.45.65
urticariatreatmentreport.com. 3600 IN NS NS Record: ns31.domaincontrol.com.
urticariatreatmentreport.com. 3600 IN NS NS Record: ns32.domaincontrol.com.
HtmlToTextCheckTime:2023-05-02 17:47:30
Urticaria Treatment Report www.UrticariaTreatmentReport.com This page keeps track of new/upcoming treatment options for chronic urticaria, also known as chronic hives. What’s in development? What’s promising? What’s available soon? Find out below… Current topics include CDX-0159, anti-KIT monoclonal antibodies, ligelizumab, and more. Subscribe Last updated: May 6, 2020 News Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020 May 6, 2020 New, previously unknown form of familial cold urticaria discovered Apr 27, 2020 Ligelizumab Improves Chronic Urticaria Symptom Control Versus Omalizumab Oct 8, 2019 Research Clinical Trials Projects Discussion Urticaria – Reddit Powered by Urgent Research Copyright © 2023 Urgent
HTTP Headers
HTTP/1.1 301 Moved Permanently
Server: nginx
Date: Mon, 25 Oct 2021 02:38:44 GMT
Content-Type: text/html
Content-Length: 162
Connection: keep-alive
Keep-Alive: timeout=20
Location: http://www.urticariatreatmentreport.com/

HTTP/1.1 301 Moved Permanently
Server: nginx
Date: Mon, 25 Oct 2021 02:38:44 GMT
Content-Type: text/html
Content-Length: 162
Connection: keep-alive
Keep-Alive: timeout=20
Location: https://www.urticariatreatmentreport.com/

HTTP/2 200 
server: nginx
date: Mon, 25 Oct 2021 02:38:44 GMT
content-type: text/html; charset=UTF-8
content-length: 34150
vary: Accept-Encoding
vary: Accept-Encoding
link: ; rel="https://api.w.org/"
link: ; rel="alternate"; type="application/json"
link: ; rel=shortlink
x-powered-by: WP Engine
x-cacheable: SHORT
vary: Accept-Encoding,Cookie
cache-control: max-age=600, must-revalidate
x-cache: HIT: 2
x-cache-group: normal
accept-ranges: bytes
urticariatreatmentreport.com Whois Information
Domain Name: URTICARIATREATMENTREPORT.COM
Registry Domain ID: 2358788597_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2021-02-08T19:57:37Z
Creation Date: 2019-02-07T06:20:41Z
Registry Expiry Date: 2022-02-07T06:20:41Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: abuse@godaddy.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS31.DOMAINCONTROL.COM
Name Server: NS32.DOMAINCONTROL.COM
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-13T07:41:05Z <<<